Cempra to Present at J.P. Morgan Healthcare Conference
January 04 2017 - 7:00AM
Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in
the treatment of bacterial infectious diseases, today announced it
will be participating in the 35th Annual J.P. Morgan Healthcare
Conference. Management is scheduled to present at 3:30 p.m. PT
(6:30 p.m. ET) on Wednesday, January 11, 2017 in San Francisco.
A live audio webcast and archive of the
presentations will be available on the company website at
http://investor.cempra.com/events.cfm. Listeners are encouraged to
visit the site prior to the scheduled presentation to register,
download and install any necessary audio software.
About Cempra, Inc.
Cempra, Inc. is a clinical-stage pharmaceutical
company focused on developing antibiotics to meet critical medical
needs in the treatment of bacterial infectious diseases. Cempra's
two lead product candidates are currently in advanced clinical
development. Solithromycin has been successfully evaluated in two
Phase 3 clinical trials for community-acquired bacterial pneumonia
(CABP). Cempra is currently seeking approval for both intravenous
and oral capsule formulations from the FDA and the EMA.
Solithromycin is licensed to strategic commercial partner Toyama
Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation,
for certain exclusive rights in Japan. Solithromycin is also in a
Phase 3 clinical trial for uncomplicated urogenital urethritis
caused by Neisseria gonorrhoeae or chlamydia. Cempra is contracted
with BARDA for the development of solithromycin for pediatric use
and has commenced enrollment in a global Phase 2/3 trial to
evaluate the safety and efficacy of solithromycin versus standard
of care antibiotics in children and adolescents from two months to
17 years of age. Fusidic acid is Cempra's second product candidate,
which has completed enrollment of an initial Phase 3 trial
comparing fusidic acid to linezolid in patients with acute
bacterial skin and skin structure infections (ABSSSI). Cempra also
has an ongoing exploratory study of fusidic acid for chronic oral
treatment of refractory infections in bones and joints. Both
products seek to address the need for new treatments targeting
drug-resistant bacterial infections in the hospital and in the
community. Cempra has also synthesized novel macrolides for
non-antibiotic uses such as the treatment of chronic inflammatory
diseases, endocrine diseases and gastric motility disorders. Cempra
was founded in 2006 and is headquartered in Chapel Hill, N.C. For
additional information about Cempra please visit
www.cempra.com.
Company Contact:
John Bluth
Cempra, Inc.
+1 984 209 4534
jbluth@cempra.com
Investor Contact:
Robert Uhl
Westwicke Partners, LLC
+1 858 356 5932
robert.uhl@westwicke.com
Media Contact:
Melyssa Weible
Elixir Health PR
+1 201 723 5805
mweible@elixirhealthpr.com
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cempra (NASDAQ:CEMP)
Historical Stock Chart
From Apr 2023 to Apr 2024